focus -WSS

focus

author：explore 2025-08-12 11:28:52 - browse：81

The Food and Drug Administration on Tuesday approved brexanolone, the first drug specifically targeted to treat postpartum depression — the most common complication of childbirth. Yet it’s a condition that often goes untreated because new mothers fear being stigmatized if they report symptoms.

Brexanolone is the first drug developed by and approved from Sage Therapeutics. The Cambridge, Mass.-based biotech company will market the new medicine under the brand name Zulresso.

“This approval is important for postpartum depression patients and it’s important for our company. It’s rare in your career when you can introduce a new medicine that is different from what’s out there,” said Sage CEO Jeff Jonas.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： CDC overhauls leadership of center that led response to Covid

WSS

The perfect storm of weather conditions that led to the devastating wildfires in Maui

Target recalls 2.2 million additional candles due to laceration, burn hazards

Naloxone nonprofit donates 200,000 doses after FDA approval

Q&A: Figuring out how songbirds sing may lead to better understanding of how humans learn

Why failed clinical trials don’t always spell doom for a new drug

Why failed clinical trials don’t always spell doom for a new drug

leisure time

focus

explore

What does generative AI mean for health care? We asked experts

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

Psychedelics group wrestles with new pharma identity

Some of the ways extreme heat will change life as we know it

Supreme Court strikes down use of affirmative action

Trump, Nauta plead not guilty to new classified docs charges but De Oliveira still not arraigned

Activists slam private health insurers over coverage restrictions

Jack Smith previously got search warrant for Trump's Twitter, new court docs show

Drug repurposing or repositioning? The language matters

An innovative path out of biotech’s “valley of death”

explore

Large hospital system sues Multiplan for low

Emergent cuts jobs, executive role in business shake

Jack Smith previously got search warrant for Trump's Twitter, new court docs show

Faced with fears of OxyContin misuse, sales reps touted its safety

Anavex keeps shifting the goalposts in its clinical trials

Why failed clinical trials don’t always spell doom for a new drug

Wikipedia

entertainment

leisure time

Wikipedia